Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | -8.90% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.82 | N/A | -8.90% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about current market dynamics and their impact on financial performance. They highlighted the importance of adapting strategies to navigate these challenges.
Management acknowledged the challenging market conditions impacting performance.
They emphasized the need for strategic adjustments moving forward.
IDEAYA Biosciences I reported a larger-than-expected loss per share, which contributed to a significant drop in stock price by 13.29%. The lack of revenue figures and guidance left investors uncertain about the company's future performance. Management's defensive tone suggests they are facing challenges that may require strategic changes.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALANTIR TECHNOLOGIE Class A
May 5, 2025